FFC#11/2019

Functional role of post-translational modifications in F508del-CFTR correction

AREA 1 Therapies to correct the underlying defect

FFC#11/2019

Functional role of post-translational modifications in F508del-CFTR correction
€ 0 still needed
0%
€ 40.000 goal

pRINCIPAL INVESTIGATOR

Mauro Salvi (Università di Padova, Dipartimento di Scienze Biomediche)

Researchers

3

Category

AREA 1 Therapies to correct the underlying defect

Duration

1 year

Goal

€ 40.000

Funds raised

€ 40.000

Objectives

Recently a cluster of post-translational modifications (PTM) associated with functional recovery of F508del, named PTM code, has been identified. In this PTM code, the phosphorylation CK2 dependent of three sites and methylation/ubiquitylation of lysine has been suggested to have a pivotal role in F508del functional rescue. However, it is not still clear if these posttranslational modifications are a consequence or are required for the recovery. The aim of the project is to assess the real contribution of these modifications for functional F508del recovery. The goal is indeed to understand if it is possible to favour F508del correction controlling these post-translational modifications. Researchers will use F508del-CFTR CFBE expressing cells. All the modified sites identified in the PTM code will be mutated. Mutants will be transfected and the rescue efficiency will be assayed. The possibility to modulate these post-translational modifications to favour F508del recovery will be investigated.

who adopted the project

Delegazione FFC di Fabriano Ancona con la Delegazione FFC di Umbertide Città di Castello

€ 40.000

Delegazione FFC di Valle Scrivia Alessandria

€ 16.000

Delegazione FFC di Montescaglioso

€ 8.000

OTHER PROJECTS

Discover the other projects

GMSG#1/2025

Developing PNAs to Block Essential Bacterial Genes and Create New Antimicrobial Therapies

FFC#1/2025

Understanding the process of epithelial-mesenchymal transition to preserve tissue function and reduce long-term complications (e.g. cancer)

FFC#2/2025

Developing RNA-targeted therapies to regulate gene expression and restore CFTR synthesis